MBX Biosciences, Inc. (NasdaqGS: MBX)
Health Care · Pharmaceuticals · US
$66.85
-2.58% today · +346.5% 1Y
MBX Biosciences, Inc. (NasdaqGS: MBX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $3.30B and employs 63 people.
Over the last twelve months the share price has gained 346.5%, trading between 9.63 and 72.64.
Tweenvest scores MBX Biosciences, Inc. across four factors: quality 34/100. Its strongest factor is quality.
MBX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.30B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.41
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $72.64
- 52-week low
- $9.63
- Avg volume (3M)
- —
- Shares outstanding
- 48.16M
- Employees
- 63
- Next earnings
- —
About MBX Biosciences, Inc.
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
- ISIN
- US55287L1017
- Founded
- 2018
- Listed since
- Sep 13, 2024
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,199.25 | -2.79% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $270.42 | -1.00% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $154.02 | -1.55% |
| Roche Holding AGSWX: ROP | $371.62B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.40 | -0.60% |
Figures last refreshed Aug 18, 2026.